Recordati Rare Diseases Inc.
Bridgewater, NJ
- UEI
- LL38YHW3Y9P4
- CAGE
- 6ZY21
- Primary NAICS
- 325411 Medicinal and Botanical Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 440 US-22 #205, Bridgewater, NJ 08807, USA
- Website
- recordatirarediseases.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $41,172 |
| FY2026 | $136,418 |
| FY2025 | $952,138 |
| FY2024 | $701,038 |
| FY2023 | $567,160 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $177,590 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Cosette Pharmaceuticals, Inc. | Bridgewater Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Ferring Pharmaceuticals Inc. | Parsippany-Troy Hills, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Alexion Pharmaceuticals Inc. | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Insmed Incorporated | Bridgewater, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Recordati Rare Diseases Inc., a foreign-owned pharmaceutical manufacturer headquartered in Bridgewater, New Jersey, supplies orphan-drug treatments for rare endocrine and metabolic disorders to the Department of Veterans Affairs as a prime contractor exclusively — all 70 recent awards are delivery orders placed under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) with no set-aside designations. The vendor competes full-and-open across the federal pharmaceutical market and holds no SBA certifications.
Recordati's federal footprint centers on a single orphan pharmaceutical: Signifor LAR (pasireotide), used to treat Cushing's disease and acromegaly, along with ancillary rare-disease medications including Isturisa (osilodrostat), Carbaglu, Cystadane, and Cystadrops. Representative delivery orders span small-unit supplies — $10.8 thousand orders for Signifor LAR 40 mg to VA facilities in Bartlett, Tennessee — to larger bulk pharmacy orders, such as a $672 thousand December 2024 delivery order from Veterans Integrated Service Network (VISN) 20 for Isturisa bulk pharmacy products and an $482 thousand 2022 order for osilodrostat tablets. The vendor maintains two underlying indefinite-delivery vehicles with the VA: a $15.6 million multiple-award Federal Supply Schedule contract running through April 2026 and a $3.16 million single-award Blanket Purchase Agreement through July 2026, both established in 2021.
Customer concentration is extreme and narrowly distributed within the VA. Veterans Integrated Service Network 5 (Nashville region) accounts for 53 awards with combined potential value of $1.3 million; VISN 20 (Pacific Northwest) accounts for 9 awards worth $2.2 million; and VISN 12 (Southern region) accounts for 3 awards with combined potential value of $35.7 million, anchored by a $672 thousand Isturisa order. The Department of Veterans Affairs National Acquisition Center places 3 awards worth $3.3 million, and VISN 21 and VISN 23 each hold one award. The source data shows the VA accounts for approximately 100% of the vendor's recent federal activity across all networks and procurement entities.
Performance occurs in Bartlett, Tennessee for distribution operations and Lebanon, New Jersey for manufacturing. The vendor operates entirely as a prime contractor — zero subcontract work appears in the source data. Activity has grown unevenly: 8 awards in 2022, 12 in 2023, 16 in 2024, 11 in 2025, and 3 in the first half of 2026. Combined potential value across all 70 awards reaches $42.6 million, though only $3.6 million (9%) has been obligated to date, reflecting the ongoing nature of delivery orders drawn against parent FSS and BPA vehicles. Three awards from VISN 12 carry completion dates through December 2025, representing potential recompete exposure in the near term.
Quick answers
Is Recordati Rare Diseases Inc. registered in SAM.gov?
Yes. Recordati Rare Diseases Inc.'s SAM.gov registration is active through August 26, 2027.
What is Recordati Rare Diseases Inc.'s CAGE code?
Recordati Rare Diseases Inc.'s CAGE code is 6ZY21, and its Unique Entity ID (UEI) is LL38YHW3Y9P4.
Which contract vehicles does Recordati Rare Diseases Inc. hold?
Recordati Rare Diseases Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Recordati Rare Diseases Inc. received in federal contracts?
Federal contracts obligated $952,138 to Recordati Rare Diseases Inc. in fiscal year 2025 and $2,397,926 in fiscal years 2023 through 2027.
How does Recordati Rare Diseases Inc. rank among federal contractors?
Recordati Rare Diseases Inc. ranked #67 in NAICS 325412 and #93 in PSC 6505 in FY2025.
What is Recordati Rare Diseases Inc.'s most recent federal award?
Recordati Rare Diseases Inc.'s most recent federal contract award is Signifor 40 MG LAR (36C24527N0110), from Veterans Integrated Service Network 5 (VHA), on October 15, 2026.
On GovTribe
See Recordati Rare Diseases Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors